Out on Yahoo Finance today -- [https://finance.yahoo.com/news/analysts-predict-400-spike-2-110500020.html](https://finance.yahoo.com/news/analysts-predict-400-spike-2-110500020.html)
"With a major catalyst ahead and ABOS shares trading at $1.98, Stifel’s 5-star analyst Paul Matteis thinks now is the right time to make a move.
“With the upcoming ph2 ALTITUDE-AD readout for sabirnetug in early Alzheimer’s expected in late 2026, ABOS has an important year ahead of them. After the stock has been largely tied to the progression of the donanemab/lecanameb launches – with shares trading at/below cash – 2026 represents a major potential inflection point for the stock… We’re encouraged by the initial data from sabirnetug’s ph1b, which illustrate that the oligomer hypothesis has the potential to clinically differentiate vs older-generation abetas. To that point, the fact that the ph2 completed enrollment on time reflects there’s continued demand from patients for novel treatments. We like the design/set-up of ALTITUDE-AD, offering a real evaluation of the oligomer mechanism across validated AD clinical scales,” Matteis noted.
To this end, Matteis rates ABOS a Buy, and his $10 price target points to a massive 405% upside over the next year.
Overall, the Street agrees that the outlook is bullish. The stock has 5 recent Buy ratings, and no Holds or Sells, forming a unanimous Strong Buy consensus. The $6.40 average target price implies a 223% gain on a one-year basis."